{"id":"doxil","rwe":[],"_fda":{"id":"cd847039-f8ab-4b90-ba4b-724504063f6f","set_id":"1c153e9e-4cf2-4ac7-9cf9-16f9b48d7dce","openfda":{"unii":["82F2G7BL4E"],"route":["INTRAVENOUS","INTRAVITREAL"],"rxcui":["1790115","1790127","1790128","1790131"],"spl_id":["cd847039-f8ab-4b90-ba4b-724504063f6f"],"brand_name":["DOXIL"],"spl_set_id":["1c153e9e-4cf2-4ac7-9cf9-16f9b48d7dce"],"package_ndc":["0338-0063-01","0338-0067-01"],"product_ndc":["0338-0063","0338-0067"],"generic_name":["DOXORUBICIN HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DOXORUBICIN HYDROCHLORIDE"],"manufacturer_name":["Baxter Healthcare Company"],"application_number":["NDA050718"],"is_original_packager":[true]},"version":"12","pregnancy":["8.1 Pregnancy Risk Summary Based on findings in animals and its mechanism of action, DOXIL liposomal infusion can cause fetal harm when administered to a pregnant woman; avoid the use of DOXIL liposomal infusion during the 1 st trimester. In animal reproduction studies, DOXIL liposomal infusion was embryotoxic in rats and abortifacient in rabbits following intravenous administration during organogenesis at doses approximately 0.12 times the recommended clinical dose (see Data ) . Available human data do not establish the presence or absence of major birth defects and miscarriage related to the use of doxorubicin hydrochloride during the 2 nd and 3 rd trimesters. Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the background risk in the U.S. general population of major birth defects is 2–4% and of miscarriage is 15–20% of clinically recognized pregnancies. Data Animal Data DOXIL liposomal infusion was embryotoxic at doses of 1 mg/kg/day in rats and was embryotoxic and abortifacient at 0.5 mg/kg/day in rabbits (both doses are about 0.12 times the recommended dose of 50 mg/m 2 human dose on a mg/m 2 basis). Embryotoxicity was characterized by increased embryo-fetal deaths and reduced live litter sizes."],"overdosage":["10 OVERDOSAGE Acute overdosage with doxorubicin hydrochloride causes increased risk of severe mucositis, leukopenia, and thrombocytopenia."],"references":["15 REFERENCES 1. “Hazardous Drugs”, OSHA, http://www.osha.gov/SLTC/hazardousdrugs/index.html"],"description":["11 DESCRIPTION The active ingredient in DOXIL liposomal infusion is doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor, that is encapsulated in STEALTH liposomes for intravenous use. The chemical name of doxorubicin hydrochloride is (8S,10S)-10-[(3-amino-2,3,6‑trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-glycolyl-7,8,9,10-tetrahydro-6,8,11‑trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride. The molecular formula is C27-H29 -NO11•HCl and the molecular weight is 579.99. The structural formula is: DOXIL liposomal infusion is a sterile, translucent, red liposomal dispersion. Each single- dose vial contains 20 mg or 50 mg doxorubicin hydrochloride at a concentration of 2 mg/mL (equivalent to 1.87 mg/mL of doxorubicin). The STEALTH liposome carriers are composed of cholesterol, 3.19 mg/mL; fully hydrogenated soy phosphatidylcholine (HSPC), 9.58 mg/mL; and N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (MPEG-DSPE), 3.19 mg/mL. Each mL also contains ammonium sulfate, approximately 0.6 mg; histidine, 1.55 mg as a buffer; hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (6.0 to 7.0); and sucrose, 94 mg to maintain isotonicity. Greater than 90% of the drug is encapsulated in the STEALTH liposomes. MPEG-DSPE has the following structural formula: HSPC has the following structural formula: Representation of a STEALTH liposome: Structural Formula MPEG-DSPE Structural Formula HSPC Structural Formula Representation of a STEALTH liposome"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING DOXIL (doxorubicin hydrochloride liposome injection) is a sterile, translucent, red liposomal dispersion in 10-mL or 30-mL glass, single-dose vials. The following individually cartoned vials are available: Table 14 vial concentration vial size NDC #s 20 mg/10 mL (2 mg/ mL) 10-mL 0338-0063-01 50 mg/25 mL (2 mg/mL) 30-mL 0338-0067-01 Refrigerate unopened vials of DOXIL (doxorubicin hydrochloride liposome injection) at 2°C- 8°C (36°F- 46°F). Do not freeze. Discard unused portion. DOXIL liposomal infusion is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1"],"boxed_warning":["WARNING: CARDIOMYOPATHY and INFUSION-RELATED REACTIONS • DOXIL liposomal infusion can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 mg/m 2 to 550 mg/m 2 . Assess left ventricular cardiac function prior to initiation of DOXIL liposomal infusion and during and after treatment [see Warnings and Precautions (5.1) ] . • Serious, life-threatening, and fatal infusion-related reactions can occur with DOXIL liposomal infusion Acute infusion-related reactions occurred in 11% of patients with solid tumors. Withhold DOXIL liposomal infusion for infusion-related reactions and resume at a reduced rate. Discontinue DOXIL liposomal infusion for serious or life-threatening infusion-related reactions [see Warnings and Precautions (5.2) ] . WARNING: CARDIOMYOPATHY and INFUSION- RELATED REACTIONS See full prescribing information for complete boxed warning. • DOXIL liposomal infusion can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 mg/m 2 to 550 mg/m 2 . Assess left ventricular cardiac function prior to initiation of DOXIL liposomal infusion, during treatment, and after treatment ( 5.1 ). • Serious, life-threatening, and fatal infusion‑related reactions can occur. Acute infusion-related reactions occurred in 11% of patients with solid tumors. Withhold DOXIL liposomal infusion for infusion-related reactions and resume at a reduced rate. Discontinue DOXIL liposomal infusion for serious or life-threatening infusion-related reactions ( 5.2 )."],"geriatric_use":["8.5 Geriatric Use Clinical studies of DOXIL liposomal infusion conducted in patients with either epithelial ovarian cancer (Trial 4) or with AIDS-related Kaposi’s sarcoma (Trial 5) did not contain sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger subjects. In Trial 6, of 318 patients treated with DOXIL liposomal infusion in combination with bortezomib for multiple myeloma, 37% were 65 years of age or older and 8% were 75 years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of DOXIL liposomal infusion in pediatric patients have not been established."],"effective_time":"20220531","clinical_studies":["14 CLINICAL STUDIES 14.1 Ovarian Cancer DOXIL liposomal infusion was studied in three open-label, single-arm, clinical studies of 176 patients with metastatic ovarian cancer (Trials 1, 2, and 3). One hundred forty-five of these patients were refractory to both paclitaxel- and platinum-based chemotherapy regimens, defined as disease progression while on treatment or relapse within 6 months of completing treatment. Patients received DOXIL liposomal infusion at 50 mg/m 2 every 3 or 4 weeks for 3–6+ cycles in the absence of dose-limiting toxicity or disease progression. The median age at diagnosis ranged from 52 to 64 years in the 3 studies, and the range was 22 to 85. Most patients had International Federation of Obstetricians and Gynecologists (FIGO) stage III or IV disease (ranging from 83% to 93%). Approximately one third of the patients had three or more prior lines of therapy (ranging from 22% to 33%). The primary outcome measure was confirmed response rate based on Southwestern Oncology Group (SWOG) criteria for patients refractory to both paclitaxel- and a platinum-containing regimen. Secondary efficacy parameters were time to response, duration of response, and time to progression. The response rates for the individual single arm trials are given in Table 9 below. Table 9: Response Rates in Patients With Refractory Ovarian Cancer From Single Arm Ovarian Cancer Trials Trial 1 (U.S.) N=27 Trial 2 (U.S.) N=82 Trial 3 (non-U.S.) N=36 Response Rate 22.2% 17.1% 0% 95% Confidence Interval 8.6% – 42.3% 9.7% – 27.0% 0.0% – 9.7% In a pooled analysis of Trials 1–3, the response rate for all patients refractory to paclitaxel and platinum agents was 13.8% (95% CI 8.1% to 19.3%). The median time to progression was 15.9 weeks, the median time to response was 17.6 weeks, and the duration of response was 39.4 weeks. In Trial 4, a randomized, multicenter, open-label, trial in 474 patients with epithelial ovarian cancer after platinum-based chemotherapy, patients were randomized to receive either DOXIL liposomal infusion 50 mg/m 2 every 4 weeks (n=239) or topotecan 1.5 mg/m 2 daily for 5 consecutive days every 3 weeks (n=235). Patients were stratified according to platinum sensitivity (response to initial platinum-based therapy and a progression-free interval of greater than 6 months off treatment) and the presence of bulky disease (tumor mass greater than 5 cm in size). The primary outcome measure was time to progression (TTP). Other endpoints included overall survival and objective response rate. Of the 474 patients, the median age at diagnosis was 60 years (range 25 to 87), 90% were FIGO stage III and IV; 46% were platinum sensitive; and 45% had bulky disease. There was no statistically significant difference in TTP between the two arms. Results are provided in Table 10 . Table 10: Results of Efficacy Analyses Analysis based on investigators' strata for protocol defined ITT population. Protocol Defined ITT Population DOXIL Liposomal Infusion (n=239) Topotecan (n=235) TTP (Protocol Specified Primary Endpoint) Median (Months) Kaplan-Meier estimates. 4.1 4.2 p-value p-value is based on the stratified log-rank test. 0.62 Hazard Ratio Hazard ratio is based on Cox proportional-hazard model with the treatment as single independent variable. A hazard ratio less than 1 indicates an advantage for DOXIL liposomal infusion. 0.96 95% CI for Hazard Ratio (0.76, 1.20) Overall Survival Median (Months) 14.4 13.7 p-value p-value not adjusted for multiple comparisons. 0.05 Hazard Ratio 0.82 95% CI for Hazard Ratio (0.68, 1.00) Response Rate Overall Response n (%) 47 (19.7) 40 (17.0) Complete Response n (%) 9 (3.8) 11 (4.7) Partial Response n (%) 38 (15.9) 29 (12.3) Median Duration of Response (Months) 6.9 5.9 14.2 AIDS-Related Kaposi’s Sarcoma DOXIL liposomal infusion was studied in an open-label, single-arm, multicenter study at a dose of 20 mg/m 2 every 3 weeks, until disease progression or unacceptable toxicity (Trial 5). Data is described for a cohort of 77 patients retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least two cycles of a regimen containing at least two of three treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy. Forty-nine of the 77 (64%) patients had received prior doxorubicin hydrochloride. The median time on study was 5.1 months (range 1 day to 15 months). The median cumulative dose of DOXIL liposomal infusion was 154 mg/m 2 (range 20 to 620 mg/m 2 ). Among the 77 patients, mean age was 38 years (range 24 to 54); 87% were Caucasian, 5% Hispanic, 4% Black, and 4% Asian/Other/Unknown; median CD4 count was 10 cells/mm 3 ; ACTG staging criteria were 78% poor risk for tumor burden, 96% poor risk for immune system, and 58% poor risk for systemic illness at baseline; and mean Karnofsky status score was 74%. All patients had cutaneous or subcutaneous lesions, 40% also had oral lesions, 26% pulmonary lesions, and 14% had lesions of the stomach/intestine. Two analyses of tumor response were used: one based on investigator assessment of changes in lesions based on modified ACTG criteria (partial response defined as no new lesions, sites of disease, or worsening edema; flattening of ≥50% of previously raised lesions or area of indicator lesions decreasing by ≥50%; and response lasting at least 21 days with no prior progression), and one based on changes in up to five prospectively indentified representative indicator lesions (partial response defined as flattening of ≥50% of previously raised indicator lesions, or >50% decrease in the area of indicator lesions and lasting at least 21 days with no prior progression). Of the 77 patients, 34 were evaluable for investigator assessment and 42 were evaluable for indicator lesion assessment; analyses of tumor responses are shown in Table 11 . Table 11: Response in Patients with Refractory Patients with disease that progressed on prior combination chemotherapy or who were intolerant to such therapy. AIDS-Related Kaposi’s Sarcoma Investigator Assessment All Evaluable Patients (n=34) Evaluable Patients Who Received Prior Doxorubicin (n=20) Response There were no complete responses in this population. Partial (PR) 27% 30% Stable 29% 40% Progression 44% 30% Duration of PR (Days) Median 73 89 Range 42+ – 210+ 42+ – 210+ Time to PR (Days) Median 43 53 Range 15 – 133 15 – 109 Indicator Lesion Assessment All Evaluable Patients (n=42) Evaluable Patients Who Received Prior Doxorubicin (n=23) Response Partial (PR) 48% 52% Stable 26% 30% Progression 26% 17% Duration of PR (Days) Median 71 79 Range 22+ – 210+ 35 – 210+ Time to PR (Days) Median 22 48 Range 15 – 109 15 – 109 Retrospective efficacy analyses were performed in two trials that had subsets of patients who received single-agent DOXIL liposomal infusion and who were on stable antiretroviral therapy for at least 60 days prior to enrollment and until a response was demonstrated. In one trial, 7 of 17 (40%) patients had a durable response (median duration not reached but was longer than 11.6 months). In the second trial, 4 of 11 patients (40%) on a stable antiretroviral therapy demonstrated durable responses. 14.3 Multiple Myeloma The efficacy of DOXIL liposomal infusion in combination with bortezomib was evaluated in Trial 6, a randomized, open-label, international, multicenter study in 646 patients who had not previously received bortezomib and whose disease progressed during or after at least one prior therapy. Patients were randomized (1:1) to receive either DOXIL liposomal infusion (30 mg/m 2 ) administered IV on day 4 following bortezomib (1.3 mg/m 2 IV on days 1, 4, 8 and 11) or bortezomib alone every 3 weeks for up to 8 cycles or until disease progression or unacceptable toxicity. Patients who maintained a response were allowed to receive further treatment. The median number of cycles in each treatment arm was 5 (range 1–18). The baseline demographics and clinical characteristics of the patients with multiple myeloma were similar between treatment arms ( Table 12 ). Table 12: Summary of Baseline Patient and Disease Characteristics Patient Characteristics DOXIL Liposomal Infusion + bortezomib n=324 bortezomib n=322 Median age in years (range) 61 (28, 85) 62 (34, 88) % Male/female 58 / 42 54 / 46 % Caucasian/Black/other 90 / 6 / 4 94 / 4 / 2 Disease Characteristics % with IgG/IgA/Light chain 57 / 27 / 12 62 / 24 / 11 % β 2 -microglobulin group ≤2.5 mg/L 14 14 >2.5 mg/L and ≤5.5 mg/L 56 55 >5.5 mg/L 30 31 Serum M-protein (g/dL): Median (Range) 2.5 (0–10.0) 2.7 (0–10.0) Urine M-protein (mg/24 hours): Median (Range) 107 (0–24883) 66 (0–39657) Median Months Since Diagnosis 35.2 37.5 % Prior Therapy One 34 34 More than one 66 66 Prior Systemic Therapies for Multiple Myeloma Corticosteroid (%) 99 >99 Anthracyclines 68 67 Alkylating agent (%) 92 90 Thalidomide/lenalidomide (%) 40 43 Stem cell transplantation (%) 57 54 The primary outcome measure was time to progression (TTP). TTP was defined as the time from randomization to the first occurrence of progressive disease or death due to progressive disease. The combination arm demonstrated significant improvement in TTP. As the prespecified primary objective was achieved at the interim analysis, patients in the bortezomib monotherapy group were then allowed to receive the DOXIL liposomal infusion + bortezomib combination. Efficacy results are as shown in Table 13 and Figure 1 . Table 13: Efficacy of DOXIL Liposomal Infusion in Combination With Bortezomib in the Treatment of Patients With Multiple Myeloma Endpoint DOXIL Liposomal Infusion + bortezomib n=324 Bortezomib n=322 Time to Progression Kaplan Meier estimate. Progression or death due to progression (n) 99 150 Censored (n) 225 172 Median in days (months) 282 (9.3) 197 (6.5) 95% CI 250; 338 170; 217 Hazard ratio Hazard ratio based on stratified Cox proportional hazards regression. A hazard ratio < 1 indicates an advantage for DOXIL liposomal infusion +bortezomib. 0.55 (95% CI) (0.43, 0.71) p-value Stratified log-rank test. <0.001 Response (n) RR as per EBMT criteria. 303 310 % Complete Response (CR) 5 3 % Partial Response (PR) 43 40 % CR + PR 48 43 p-value Cochran-Mantel-Haenszel test adjusted for the stratification factors. 0.25 Median Duration of Response (months) 10.2 7.0 (95% CI) (10.2; 12.9) (5.9; 8.3) Figure 1 - Time to Progression Kaplan-Meier Curve At the final analysis of survival, 78% of subjects in the DOXIL liposomal infusion and bortezomib combination therapy group and 80% of subjects in the bortezomib monotherapy group had died after a median follow up of 8.6 years. The median survival was 33 months in the DOXIL liposomal infusion and bortezomib combination therapy group and 31 months in the bortezomib monotherapy group. There was no difference observed in overall survival at the final analysis [HR for DOXIL liposomal infusion + bortezomib vs. bortezomib = 0.96 (95% CI 0.80, 1.14)]. Seventy-eight percent of subjects in the DOXIL liposomal infusion and bortezomib combination therapy group and 80% of subjects in the bortezomib monotherapy group had received subsequent therapy. Figure 1"],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetic parameters for total doxorubicin following a single dose of DOXIL infused over 30 minutes are presented in Table 8 . Table 8: Pharmacokinetic Parameters of Total Doxorubicin from DOXIL Liposomal Infusion in Patients With AIDS-Related Kaposi’s Sarcoma Dose Parameter (units) 10 mg/m 2 20 mg/m 2 N=23 Mean ± Standard Error Peak Plasma Concentration (µg/mL) 4.12 ± 0.215 8.34 ± 0.49 Plasma Clearance (L/h/m 2 ) 0.056 ± 0.01 0.041 ± 0.004 Steady State Volume of Distribution (L/m 2 ) 2.83 ± 0.145 2.72 ± 0.120 AUC (µg/mL∙h) 277 ± 32.9 590 ± 58.7 First Phase (λ 1 ) Half-Life (h) 4.7 ± 1.1 5.2 ± 1.4 Second Phase (λ 1 ) Half-Life (h) 52.3 ± 5.6 55.0 ± 4.8 DOXIL liposomal infusion displayed linear pharmacokinetics over the range of 10 to 20 mg/m 2 . Relative to DOXIL liposomal infusion doses at or below 20 mg/m 2 , the pharmacokinetics of total doxorubicin following a 50 mg/m 2 DOXIL liposomal infusion dose are nonlinear. At this dose, the elimination half-life of DOXIL liposomal infusion is longer and the clearance lower compared to a 20 mg/m 2 dose. Distribution Direct measurement of liposomal doxorubicin shows that at least 90% of the drug (the assay used cannot quantify less than 5–10% free doxorubicin) remains liposome-encapsulated during circulation. In contrast to doxorubicin, which displays a large volume of distribution (range 700 to 1100 L/m 2 ), the small steady state volume of distribution of liposomal doxorubicin suggests that DOXIL liposomal infusion is largely confined to vascular fluid. Doxorubicin becomes available after the liposomes are extravasated. Plasma protein binding of DOXIL liposomal infusion has not been determined; the plasma protein binding of doxorubicin is approximately 70%. Metabolism Doxorubicinol, the major metabolite of doxorubicin, was detected at concentrations of 0.8 to 26.2 ng/mL in the plasma of patients who received 10 or 20 mg/m 2 DOXIL liposomal infusion. Elimination The plasma clearance of total doxorubicin from DOXIL liposomal infusion was 0.041 L/h/m 2 at a dose of 20 mg/m 2 . Following administration of doxorubicin hydrochloride, the plasma clearance of doxorubicin is 24 to 35 L/h/m 2 ."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling. • Cardiomyopathy [see Warnings and Precautions (5.1) ] • Infusion-Related Reactions [see Warnings and Precautions (5.2) ] • Hand-Foot Syndrome [see Warnings and Precautions (5.3) ] • Secondary Oral Neoplasms [see Warnings and Precautions (5.4) ] Most common adverse reactions (>20%) are asthenia, fatigue, fever, anorexia, nausea, vomiting, stomatitis, diarrhea, constipation, hand-foot syndrome, rash, neutropenia, thrombocytopenia, and anemia ( 6 ). To report SUSPECTED ADVERSE REACTIONS contact Baxter Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates on other clinical trials and may not reflect the rates observed in clinical practice. The safety data reflect exposure to DOXIL liposomal infusion in 1310 patients including: 239 patients with ovarian cancer, 753 patients with AIDS-related Kaposi’s sarcoma, and 318 patients with multiple myeloma. The most common adverse reactions (>20%) observed with DOXIL liposomal infusion are asthenia, fatigue, fever, nausea, stomatitis, vomiting, diarrhea, constipation, anorexia, hand-foot syndrome, rash and neutropenia, thrombocytopenia and anemia. The following tables present adverse reactions from clinical trials of single-agent DOXIL liposomal infusion in ovarian cancer and AIDS-Related Kaposi’s sarcoma. Patients With Ovarian Cancer The safety data described below are from Trial 4, which included 239 patients with ovarian cancer treated with DOXIL liposomal infusion 50 mg/m 2 once every 4 weeks for a minimum of four courses in a randomized, multicenter, open-label study. In this trial, patients received DOXIL liposomal infusion for a median number of 3.2 months (range 1 day to 25.8 months). The median age of the patients is 60 years (range 27 to 87), with 91% Caucasian, 6% Black, and 3% Hispanic or Other. Table 3 presents the hematologic adverse reactions from Trial 4. Table 3: Hematologic Adverse Reactions in Trial 4 DOXIL Liposomal Infusion Patients (n=239) Topotecan Patients (n=235) Neutropenia 500 – <1000/mm 3 8% 14% <500/mm 3 4.2% 62% Anemia 6.5 – <8 g/dL 5% 25% < 6.5 g/dL 0.4% 4.3% Thrombocytopenia 10,000 – <50,000/mm 3 1.3% 17% <10,000/mm 3 0.0% 17% Table 4 presents the non-hematologic adverse reactions from Trial 4. Table 4: Non-Hematologic Adverse Reactions in Trial 4 Non-Hematologic Adverse Reaction 10% or Greater DOXIL Liposomal Infusion (%) treated (n=239) Topotecan (%) treated (n=235) All grades Grades 3–4 All grades Grades 3–4 Body as a Whole Asthenia 40 7 52 8 Fever 21 0.8 31 6 Mucous Membrane Disorder 14 3.8 3.4 0 Back Pain 12 1.7 10 0.9 Infection 12 2.1 6 0.9 Headache 11 0.8 15 0 Digestive Nausea 46 5 63 8 Stomatitis 41 8 15 0.4 Vomiting 33 8 44 10 Diarrhea 21 2.5 35 4.2 Anorexia 20 2.5 22 1.3 Dyspepsia 12 0.8 14 0 Nervous Dizziness 4.2 0 10 0 Respiratory Pharyngitis 16 0 18 0.4 Dyspnea 15 4.1 23 4.3 Cough increased 10 0 12 0 Skin and Appendages Hand-foot syndrome 51 24 0.9 0 Rash 29 4.2 12 0.4 Alopecia 19 N/A 52 N/A The following additional adverse reactions were observed in patients with ovarian cancer with doses administered every four weeks (Trial 4). Incidence 1% to 10% Cardiovascular: vasodilation, tachycardia, deep vein thrombosis, hypotension, cardiac arrest. Digestive: oral moniliasis, mouth ulceration, esophagitis, dysphagia, rectal bleeding, ileus. Hematologic and Lymphatic: ecchymosis. Metabolic and Nutritional: dehydration, weight loss, hyperbilirubinemia, hypokalemia, hypercalcemia, hyponatremia. Nervous: somnolence, dizziness, depression. Respiratory: rhinitis, pneumonia, sinusitis, epistaxis. Skin and Appendages: pruritus, skin discoloration, vesiculobullous rash, maculopapular rash, exfoliative dermatitis, herpes zoster, dry skin, herpes simplex, fungal dermatitis, furunculosis, acne. Special Senses: conjunctivitis, taste perversion, dry eyes. Urinary: urinary tract infection, hematuria, vaginal moniliasis. Patients With AIDS-Related Kaposi’s Sarcoma The safety data described is based on the experience reported in 753 patients with AIDS-related Kaposi’s sarcoma (KS) enrolled in four open-label, uncontrolled trials of DOXIL liposomal infusion administered at doses ranging from 10 to 40 mg/m 2 every 2 to 3 weeks. Demographics of the population were: median age 38.7 years (range 24–70); 99% male; 88% Caucasian, 6% Hispanic, 4% Black, and 2% Asian/other/unknown. The majority of patients were treated with 20 mg/m 2 of DOXIL liposomal infusion every 2 to 3 weeks with a median exposure of 4.2 months (range 1 day to 26.6 months). The median cumulative dose was 120 mg/m 2 (range 3.3 to 798.6 mg/m 2 ); 3% received cumulative doses of greater than 450 mg/m 2 . Disease characteristics were: 61% poor risk for KS tumor burden, 91% poor risk for immune system, and 47% poor risk for systemic illness; 36% were poor risk for all three categories; median CD4 count 21 cells/mm 3 (51% less than 50 cells/mm 3 ); mean absolute neutrophil count at study entry approximately 3,000 cells/mm 3 . Of the 693 patients with concomitant medication information, 59% were on one or more antiretroviral medications [35% zidovudine (AZT), 21% didanosine (ddI), 16% zalcitabine (ddC), and 10% stavudine (D4T)]; 85% received PCP prophylaxis (54% sulfamethoxazole/trimethoprim); 85% received antifungal medications (76% fluconazole); 72% received antivirals (56% acyclovir, 29% ganciclovir, and 16% foscarnet) and 48% patients received colony-stimulating factors (sargramostim/filgrastim) during their course of treatment. Adverse reactions led to discontinuation of treatment in 5% of patients with AIDS-related Kaposi’s sarcoma and included myelosuppression, cardiac adverse reactions, infusion-related reactions, toxoplasmosis, HFS, pneumonia, cough/dyspnea, fatigue, optic neuritis, progression of a non-KS tumor, allergy to penicillin, and unspecified reasons. Table 5 and Table 6 summarize adverse reactions reported in patients treated with DOXIL liposomal infusion for AIDS-related Kaposi’s sarcoma in a pooled analysis of the four trials. Table 5: Hematologic Adverse Reactions Reported in Patients With AIDS-Related Kaposi’s Sarcoma Patients With Refractory or Intolerant AIDS-Related Kaposi’s Sarcoma (n=74 This includes a subset of subjects who were retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least 2 cycles of a regimen containing at least 2 of 3 treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy. ) Total Patients With AIDS-Related Kaposi’s Sarcoma (n=720 This includes only subjects with AIDS-KS who had available data from the 4 pooled trials. ) Neutropenia < 1000/mm 3 46% 49% < 500/mm 3 11% 13% Anemia < 10 g/dL 58% 55% < 8 g/dL 16% 18% Thrombocytopenia < 150,000/mm 3 61% 61% < 25,000/mm 3 1.4% 4.2% Table 6: Non-Hematologic Adverse Reactions Reported in ≥ 5% of Patients With AIDS-Related Kaposi’s Sarcoma Adverse Reactions Patients With Refractory or Intolerant AIDS-Related Kaposi’s Sarcoma (n=77 This includes a subset of subjects who were retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least 2 cycles of a regimen containing at least 2 of 3 treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy. ) Total Patients With AIDS-Related Kaposi’s Sarcoma (n=705 This includes only subjects with AIDS-KS who had available adverse event data from the 4 pooled trials. ) Nausea 18% 17% Asthenia 7% 10% Fever 8% 9% Alopecia 9% 9% Alkaline Phosphatase Increase 1.3% 8% Vomiting 8% 8% Diarrhea 5% 8% Stomatitis 5% 7% Oral Moniliasis 1.3% 6% The following additional adverse reactions were observed in 705 patients with AIDS-related Kaposi’s sarcoma. Incidence 1% to 5% Body as a Whole: headache, back pain, infection, allergic reaction, chills. Cardiovascular: chest pain, hypotension, tachycardia. Cutaneous: herpes simplex, rash, itching. Digestive: mouth ulceration, anorexia, dysphagia. Metabolic and Nutritional: SGPT increase, weight loss, hyperbilirubinemia. Other: dyspnea, pneumonia, dizziness, somnolence. Incidence Less Than 1% Body As A Whole: sepsis, moniliasis, cryptococcosis. Cardiovascular: thrombophlebitis, cardiomyopathy, palpitation, bundle branch block, congestive heart failure, heart arrest, thrombosis, ventricular arrhythmia. Digestive: hepatitis. Metabolic and Nutritional Disorders: dehydration. Respiratory: cough increase, pharyngitis. Skin and Appendages: maculopapular rash, herpes zoster. Special Senses: taste perversion, conjunctivitis. Patients With Multiple Myeloma The safety data described are from 318 patients treated with DOXIL liposomal infusion (30 mg/m 2 ) administered on day 4 following bortezomib (1.3 mg/m 2 i.v. bolus on days 1, 4, 8 and 11) every 3 weeks, in a randomized, open-label, multicenter study (Trial 6). In this trial, patients in the DOXIL liposomal infusion + bortezomib combination group were treated for a median number of 4.5 months (range 21 days to 13.5 months). The population was 28 to 85 years of age (median age 61), 58% male, 90% Caucasian, 6% Black, and 4% Asian and Other. Table 7 lists adverse reactions reported in 10% or more of patients treated with DOXIL liposomal infusion in combination with bortezomib for multiple myeloma. Table 7: Frequency of Treatment-Emergent Adverse Reactions Reported in ≥10% Patients Treated for Multiple Myeloma With DOXIL Liposomal Infusion in Combination With Bortezomib Adverse Reaction DOXIL Liposomal Infusion + bortezomib (n=318) Bortezomib (n=318) Any (%) Grade 3–4 Any (%) Grade 3–4 Blood and lymphatic system disorders Neutropenia 36 32 22 16 Thrombocytopenia 33 24 28 17 Anemia 25 9 21 9 General disorders and administration site conditions Fatigue 36 7 28 3 Pyrexia 31 1 22 1 Asthenia 22 6 18 4 Gastrointestinal disorders Nausea 48 3 40 1 Diarrhea 46 7 39 5 Vomiting 32 4 22 1 Constipation 31 1 31 1 Mucositis/Stomatitis 20 2 5 <1 Abdominal pain 11 1 8 1 Infections and infestations Herpes zoster 11 2 9 2 Herpes simplex 10 0 6 1 Investigations Weight decreased 12 0 4 0 Metabolism and Nutritional disorders Anorexia 19 2 14 <1 Nervous system disorders Peripheral Neuropathy Peripheral neuropathy includes the following adverse reactions: peripheral sensory neuropathy, neuropathy peripheral, polyneuropathy, peripheral motor neuropathy, and neuropathy NOS. 42 7 45 11 Neuralgia 17 3 20 4 Paresthesia/dysesthesia 13 <1 10 0 Respiratory, thoracic and mediastinal disorders Cough 18 0 12 0 Skin and subcutaneous tissue disorders Rash Rash includes the following adverse reactions: rash, rash erythematous, rash macular, rash maculo-papular, rash pruritic, exfoliative rash, and rash generalized. 22 1 18 1 Hand-foot syndrome 19 6 <1 0 6.2 Postmarketing Experience The following additional adverse reactions have been identified during postapproval use of DOXIL liposomal infusion. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Musculoskeletal and Connective Tissue Disorders: muscle spasms Respiratory, Thoracic and Mediastinal Disorders: pulmonary embolism (in some cases fatal) Hematologic Disorders: Secondary acute myelogenous leukemia Skin and Subcutaneous Tissue Disorders: erythema multiforme, Stevens‑Johnson syndrome, toxic epidermal necrolysis, lichenoid keratosis Secondary Oral Neoplasms: [see Warnings and Precautions (5.4) ]."],"contraindications":["4 CONTRAINDICATIONS DOXIL liposomal infusion is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see Warnings and Precautions (5.2) ]. • Hypersensitivity reactions to doxorubicin hydrochloride or the components of DOXIL liposomal infusion ( 4 , 5.2 )"],"drug_interactions":["7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with DOXIL liposomal infusion."],"how_supplied_table":["
Table 14
vial concentrationvial sizeNDC #s
20 mg/10 mL(2 mg/ mL)10-mL0338-0063-01
50 mg/25 mL(2 mg/mL)30-mL0338-0067-01
"],"mechanism_of_action":["12.1 Mechanism of Action The active ingredient of DOXIL liposomal infusion is doxorubicin hydrochloride. The mechanism of action of doxorubicin hydrochloride is thought to be related to its ability to bind DNA and inhibit nucleic acid synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and induction of mutagenesis and chromosomal aberrations."],"storage_and_handling":["Refrigerate unopened vials of DOXIL (doxorubicin hydrochloride liposome injection) at 2°C- 8°C (36°F- 46°F). Do not freeze. Discard unused portion. DOXIL liposomal infusion is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The active ingredient of DOXIL liposomal infusion is doxorubicin hydrochloride. The mechanism of action of doxorubicin hydrochloride is thought to be related to its ability to bind DNA and inhibit nucleic acid synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and induction of mutagenesis and chromosomal aberrations. 12.3 Pharmacokinetics The pharmacokinetic parameters for total doxorubicin following a single dose of DOXIL infused over 30 minutes are presented in Table 8 . Table 8: Pharmacokinetic Parameters of Total Doxorubicin from DOXIL Liposomal Infusion in Patients With AIDS-Related Kaposi’s Sarcoma Dose Parameter (units) 10 mg/m 2 20 mg/m 2 N=23 Mean ± Standard Error Peak Plasma Concentration (µg/mL) 4.12 ± 0.215 8.34 ± 0.49 Plasma Clearance (L/h/m 2 ) 0.056 ± 0.01 0.041 ± 0.004 Steady State Volume of Distribution (L/m 2 ) 2.83 ± 0.145 2.72 ± 0.120 AUC (µg/mL∙h) 277 ± 32.9 590 ± 58.7 First Phase (λ 1 ) Half-Life (h) 4.7 ± 1.1 5.2 ± 1.4 Second Phase (λ 1 ) Half-Life (h) 52.3 ± 5.6 55.0 ± 4.8 DOXIL liposomal infusion displayed linear pharmacokinetics over the range of 10 to 20 mg/m 2 . Relative to DOXIL liposomal infusion doses at or below 20 mg/m 2 , the pharmacokinetics of total doxorubicin following a 50 mg/m 2 DOXIL liposomal infusion dose are nonlinear. At this dose, the elimination half-life of DOXIL liposomal infusion is longer and the clearance lower compared to a 20 mg/m 2 dose. Distribution Direct measurement of liposomal doxorubicin shows that at least 90% of the drug (the assay used cannot quantify less than 5–10% free doxorubicin) remains liposome-encapsulated during circulation. In contrast to doxorubicin, which displays a large volume of distribution (range 700 to 1100 L/m 2 ), the small steady state volume of distribution of liposomal doxorubicin suggests that DOXIL liposomal infusion is largely confined to vascular fluid. Doxorubicin becomes available after the liposomes are extravasated. Plasma protein binding of DOXIL liposomal infusion has not been determined; the plasma protein binding of doxorubicin is approximately 70%. Metabolism Doxorubicinol, the major metabolite of doxorubicin, was detected at concentrations of 0.8 to 26.2 ng/mL in the plasma of patients who received 10 or 20 mg/m 2 DOXIL liposomal infusion. Elimination The plasma clearance of total doxorubicin from DOXIL liposomal infusion was 0.041 L/h/m 2 at a dose of 20 mg/m 2 . Following administration of doxorubicin hydrochloride, the plasma clearance of doxorubicin is 24 to 35 L/h/m 2 ."],"indications_and_usage":["1 INDICATIONS AND USAGE Doxil liposomal infusion is an anthracycline topoisomerase inhibitor indicated for: • Ovarian cancer: After failure of platinum-based chemotherapy ( 1.1 ) • AIDS-related Kaposi’s Sarcoma: After failure of prior systemic chemotherapy or intolerance to such therapy ( 1.2 ) • Multiple Myeloma: In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ) 1.1 Ovarian Cancer DOXIL liposomal infusion is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. 1.2 AIDS-Related Kaposi’s Sarcoma DOXIL liposomal infusion is indicated for the treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. 1.3 Multiple Myeloma DOXIL liposomal infusion, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Hand-Foot Syndrome may occur. Dose modification or discontinuation may be required ( 5.3 ) • Embryo-Fetal Toxicity: Can cause fetal harm. Advise of potential risk to a fetus. Use effective contraception ( 5.5 , 8.1 , 8.3 ) 5.1 Cardiomyopathy Doxorubicin hydrochloride can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy with doxorubicin hydrochloride is generally proportional to the cumulative exposure. Include prior use of other anthracyclines or anthracenediones in calculations of cumulative dose. The risk of cardiomyopathy may be increased at lower cumulative doses in patients with prior mediastinal irradiation. In a clinical study in 250 patients with advanced cancer who were treated with DOXIL liposomal infusion, the risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 mg/m 2 to 550 mg/m 2 . Cardiomyopathy was defined as >20% decrease in resting left ventricular ejection fraction (LVEF) from baseline where LVEF remained in the normal range or a >10% decrease in LVEF from baseline where LVEF was less than the institutional lower limit of normal. Two percent of patients developed signs and symptoms of congestive heart failure without documented evidence of cardiomyopathy. Assess left ventricular cardiac function (e.g. MUGA or echocardiogram) prior to initiation of DOXIL liposomal infusion, during treatment to detect acute changes, and after treatment to detect delayed cardiomyopathy. Administer DOXIL liposomal infusion to patients with a history of cardiovascular disease only when the potential benefit of treatment outweighs the risk. 5.2 Infusion-Related Reactions Serious, life-threatening, and fatal infusion-related reactions characterized by one or more of the following symptoms can occur with DOXIL liposomal infusion: flushing, shortness of breath, facial swelling, headache, chills, chest pain, back pain, tightness in the chest and throat, fever, tachycardia, pruritus, rash, cyanosis, syncope, bronchospasm, asthma, apnea, and hypotension. Of 239 patients with ovarian cancer treated with DOXIL liposomal infusion in Trial 4, 7% of patients experienced acute infusion-related reactions resulting in dose interruption. All occurred during cycle 1 and none during subsequent cycles. Across multiple studies of DOXIL liposomal infusion monotherapy including this and other studies enrolling 760 patients with various solid tumors, 11% of patients had infusion-related reactions. The majority of infusion-related events occurred during the first infusion. Ensure that medications to treat infusion-related reactions and cardiopulmonary resuscitative equipment are available for immediate use prior to initiation of DOXIL liposomal infusion. Initiate DOXIL liposomal infusions at a rate of 1 mg/min and increase rate as tolerated [see Dosage and Administration (2.6) ] . Withhold DOXIL liposomal infusion for Grade 1, 2, or 3 infusion-related reactions and resume at a reduced infusion rate. Discontinue DOXIL liposomal infusion for serious or life-threatening infusion-related reactions. 5.3 Hand-Foot Syndrome (HFS) In Trial 4, the incidence of HFS was 51% of patients in the DOXIL liposomal infusion arm and 0.9% of patients in the topotecan arm, including 24% Grade 3 or 4 cases of HFS in DOXIL liposomal infusion-treated patients and no Grade 3 or 4 cases in topotecan-treated patients. HFS or other skin toxicity required discontinuation of DOXIL liposomal infusion in 4.2% of patients. HFS was generally observed after 2 or 3 cycles of treatment but may occur earlier. Delay DOXIL liposomal infusion for the first episode of Grade 2 or greater HFS [see Dosage and Administration (2.5) ] . Discontinue DOXIL liposomal infusion if HFS is severe and debilitating. 5.4 Secondary Oral Neoplasms Secondary oral cancers, primarily squamous cell carcinoma, have been reported from post-marketing experience in patients with long-term (more than one year) exposure to DOXIL liposomal infusion. These malignancies were diagnosed both during treatment with DOXIL liposomal infusion and up to 6 years after the last dose. Examine patients at regular intervals for the presence of oral ulceration or with any oral discomfort that may be indicative of secondary oral cancer. The altered pharmacokinetics and preferential tissue distribution of liposomal doxorubicin that contributes to enhanced skin toxicity and mucositis compared to free doxorubicin may play a role in the development of oral secondary malignancies with long-term use. 5.5 Embryo-Fetal Toxicity Based on findings in animals and its mechanism of action, DOXIL liposomal infusion can cause fetal harm when administered to a pregnant woman; avoid the use of DOXIL liposomal infusion during the 1 st trimester. Available human data do not establish the presence or absence of major birth defects and miscarriage related to the use of doxorubicin hydrochloride during the 2 nd and 3 rd trimesters. At doses approximately 0.12 times the recommended clinical dose, DOXIL liposomal infusion was embryotoxic and abortifacient in rabbits. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during and for 6 months after treatment with DOXIL liposomal infusion [see Use in Specific Populations (8.1 , 8.3 )] ."],"clinical_studies_table":["
Table 9: Response Rates in Patients With Refractory Ovarian Cancer From Single Arm Ovarian Cancer Trials
Trial 1 (U.S.) N=27Trial 2 (U.S.) N=82Trial 3 (non-U.S.) N=36
Response Rate22.2%17.1%0%
95% Confidence Interval8.6% – 42.3%9.7% – 27.0%0.0% – 9.7%
","
Table 10: Results of Efficacy AnalysesAnalysis based on investigators' strata for protocol defined ITT population.
Protocol Defined ITT Population
DOXIL Liposomal Infusion (n=239)Topotecan (n=235)
TTP (Protocol Specified Primary Endpoint)
Median (Months)Kaplan-Meier estimates.4.14.2
p-valuep-value is based on the stratified log-rank test.0.62
Hazard RatioHazard ratio is based on Cox proportional-hazard model with the treatment as single independent variable. A hazard ratio less than 1 indicates an advantage for DOXIL liposomal infusion.0.96
95% CI for Hazard Ratio(0.76, 1.20)
Overall Survival
Median (Months) 14.413.7
p-valuep-value not adjusted for multiple comparisons.0.05
Hazard Ratio0.82
95% CI for Hazard Ratio(0.68, 1.00)
Response Rate
Overall Response n (%)47 (19.7)40 (17.0)
Complete Response n (%)9 (3.8)11 (4.7)
Partial Response n (%)38 (15.9)29 (12.3)
Median Duration of Response (Months) 6.95.9
","
Table 11: Response in Patients with RefractoryPatients with disease that progressed on prior combination chemotherapy or who were intolerant to such therapy. AIDS-Related Kaposi’s Sarcoma
Investigator AssessmentAll Evaluable Patients (n=34)Evaluable Patients Who Received Prior Doxorubicin (n=20)
ResponseThere were no complete responses in this population.
Partial (PR)27%30%
Stable29%40%
Progression44%30%
Duration of PR (Days)
Median7389
Range42+ – 210+42+ – 210+
Time to PR (Days)
Median4353
Range15 – 13315 – 109
Indicator Lesion AssessmentAll Evaluable Patients (n=42)Evaluable Patients Who Received Prior Doxorubicin (n=23)
Response
Partial (PR)48%52%
Stable26%30%
Progression26%17%
Duration of PR (Days)
Median7179
Range22+ – 210+35 – 210+
Time to PR (Days)
Median2248
Range15 – 10915 – 109
","
Table 12: Summary of Baseline Patient and Disease Characteristics
Patient CharacteristicsDOXIL Liposomal Infusion + bortezomib n=324bortezomib n=322
Median age in years (range)61 (28, 85)62 (34, 88)
% Male/female 58 / 4254 / 46
% Caucasian/Black/other 90 / 6 / 494 / 4 / 2
Disease Characteristics
% with IgG/IgA/Light chain 57 / 27 / 1262 / 24 / 11
% β2-microglobulin group
≤2.5 mg/L1414
>2.5 mg/L and ≤5.5 mg/L5655
>5.5 mg/L3031
Serum M-protein (g/dL): Median (Range)2.5 (0–10.0)2.7 (0–10.0)
Urine M-protein (mg/24 hours): Median (Range)107 (0–24883)66 (0–39657)
Median Months Since Diagnosis35.237.5
% Prior Therapy
One3434
More than one6666
Prior Systemic Therapies for Multiple Myeloma
Corticosteroid (%)99>99
Anthracyclines6867
Alkylating agent (%)9290
Thalidomide/lenalidomide (%)4043
Stem cell transplantation (%)5754
","
Table 13: Efficacy of DOXIL Liposomal Infusion in Combination With Bortezomib in the Treatment of Patients With Multiple Myeloma
EndpointDOXIL Liposomal Infusion + bortezomib n=324Bortezomib n=322
Time to ProgressionKaplan Meier estimate.
Progression or death due to progression (n)99150
Censored (n)225172
Median in days (months)282 (9.3)197 (6.5)
95% CI250; 338170; 217
Hazard ratioHazard ratio based on stratified Cox proportional hazards regression. A hazard ratio < 1 indicates an advantage for DOXIL liposomal infusion +bortezomib.0.55
(95% CI)(0.43, 0.71)
p-valueStratified log-rank test.<0.001
Response (n)RR as per EBMT criteria.303310
% Complete Response (CR) 53
% Partial Response (PR) 4340
% CR + PR4843
p-valueCochran-Mantel-Haenszel test adjusted for the stratification factors.0.25
Median Duration of Response (months)10.27.0
(95% CI)(10.2; 12.9)(5.9; 8.3)
","
Figure 1 - Time to Progression Kaplan-Meier Curve
"],"nonclinical_toxicology":["13 NON-CLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility Mutagenicity or carcinogenicity studies have not been conducted with DOXIL liposomal infusion, however doxorubicin was shown to be mutagenic in the in vitro Ames assay, and clastogenic in multiple in vitro assays (CHO cell, V79 hamster cell, human lymphoblast, and SCE assays) and the in vivo mouse micronucleus assay. The possible adverse effects on fertility in animals have not been adequately evaluated. DOXIL liposomal infusion resulted in mild to moderate ovarian and testicular atrophy in mice after administration of a single dose of 36 mg/kg (about 2 times the 50 mg/m 2 human dose on a mg/m 2 basis). Decreased testicular weights and hypospermia were observed in rats after repeat doses ≥ 0.25 mg/kg/day (about 0.03 times the 50 mg/m 2 human dose on a mg/m 2 basis), and diffuse degeneration of the seminiferous tubules and a marked decrease in spermatogenesis were observed in dogs after repeat doses of 1 mg/kg/day (about 0.4 times the 50 mg/m 2 human dose on a mg/m 2 basis)."],"pharmacokinetics_table":["
Table 8: Pharmacokinetic Parameters of Total Doxorubicin from DOXIL Liposomal Infusion in Patients With AIDS-Related Kaposi’s Sarcoma
Dose
Parameter (units)10 mg/m220 mg/m2
N=23 Mean ± Standard Error
Peak Plasma Concentration (µg/mL)4.12 ± 0.2158.34 ± 0.49
Plasma Clearance (L/h/m2)0.056 ± 0.010.041 ± 0.004
Steady State Volume of Distribution (L/m2)2.83 ± 0.1452.72 ± 0.120
AUC (µg/mL∙h)277 ± 32.9590 ± 58.7
First Phase (λ1) Half-Life (h)4.7 ± 1.15.2 ± 1.4
Second Phase (λ1) Half-Life (h)52.3 ± 5.655.0 ± 4.8
"],"adverse_reactions_table":["
Table 3: Hematologic Adverse Reactions in Trial 4
DOXIL Liposomal Infusion Patients (n=239)Topotecan Patients (n=235)
Neutropenia
500 – <1000/mm38%14%
<500/mm34.2%62%
Anemia
6.5 – <8 g/dL5%25%
< 6.5 g/dL0.4%4.3%
Thrombocytopenia
10,000 – <50,000/mm31.3%17%
<10,000/mm30.0%17%
","
Table 4: Non-Hematologic Adverse Reactions in Trial 4
Non-Hematologic Adverse Reaction 10% or GreaterDOXIL Liposomal Infusion (%) treated (n=239)Topotecan (%) treated (n=235)
All gradesGrades 3–4All gradesGrades 3–4
Body as a Whole
Asthenia407528
Fever210.8316
Mucous Membrane Disorder143.83.40
Back Pain121.7100.9
Infection122.160.9
Headache110.8150
Digestive
Nausea465638
Stomatitis418150.4
Vomiting3384410
Diarrhea212.5354.2
Anorexia202.5221.3
Dyspepsia120.8140
Nervous
Dizziness4.20100
Respiratory
Pharyngitis160180.4
Dyspnea154.1234.3
Cough increased100120
Skin and Appendages
Hand-foot syndrome51240.90
Rash294.2120.4
Alopecia19N/A52N/A
","
Table 5: Hematologic Adverse Reactions Reported in Patients With AIDS-Related Kaposi’s Sarcoma
Patients With Refractory or Intolerant AIDS-Related Kaposi’s Sarcoma (n=74This includes a subset of subjects who were retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least 2 cycles of a regimen containing at least 2 of 3 treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy.)Total Patients With AIDS-Related Kaposi’s Sarcoma (n=720This includes only subjects with AIDS-KS who had available data from the 4 pooled trials.)
Neutropenia
< 1000/mm346%49%
< 500/mm311%13%
Anemia
< 10 g/dL58%55%
< 8 g/dL16%18%
Thrombocytopenia
< 150,000/mm361%61%
< 25,000/mm31.4%4.2%
","
Table 6: Non-Hematologic Adverse Reactions Reported in ≥ 5% of Patients With AIDS-Related Kaposi’s Sarcoma
Adverse ReactionsPatients With Refractory or Intolerant AIDS-Related Kaposi’s Sarcoma (n=77This includes a subset of subjects who were retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least 2 cycles of a regimen containing at least 2 of 3 treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy.)Total Patients With AIDS-Related Kaposi’s Sarcoma (n=705This includes only subjects with AIDS-KS who had available adverse event data from the 4 pooled trials.)
Nausea18%17%
Asthenia7%10%
Fever8%9%
Alopecia9%9%
Alkaline Phosphatase Increase1.3%8%
Vomiting8%8%
Diarrhea5%8%
Stomatitis5%7%
Oral Moniliasis1.3%6%
","
Table 7: Frequency of Treatment-Emergent Adverse Reactions Reported in ≥10% Patients Treated for Multiple Myeloma With DOXIL Liposomal Infusion in Combination With Bortezomib
Adverse ReactionDOXIL Liposomal Infusion + bortezomib (n=318)Bortezomib (n=318)
Any (%)Grade 3–4Any (%)Grade 3–4
Blood and lymphatic system disorders
Neutropenia36322216
Thrombocytopenia33242817
Anemia259219
General disorders and administration site conditions
Fatigue367283
Pyrexia311221
Asthenia226184
Gastrointestinal disorders
Nausea483401
Diarrhea467395
Vomiting324221
Constipation311311
Mucositis/Stomatitis2025<1
Abdominal pain11181
Infections and infestations
Herpes zoster11292
Herpes simplex10061
Investigations
Weight decreased12040
Metabolism and Nutritional disorders
Anorexia19214<1
Nervous system disorders
Peripheral NeuropathyPeripheral neuropathy includes the following adverse reactions: peripheral sensory neuropathy, neuropathy peripheral, polyneuropathy, peripheral motor neuropathy, and neuropathy NOS.4274511
Neuralgia173204
Paresthesia/dysesthesia13<1100
Respiratory, thoracic and mediastinal disorders
Cough180120
Skin and subcutaneous tissue disorders
RashRash includes the following adverse reactions: rash, rash erythematous, rash macular, rash maculo-papular, rash pruritic, exfoliative rash, and rash generalized.221181
Hand-foot syndrome196<10
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Cardiomyopathy Advise patients to contact their healthcare provider if they develop symptoms of heart failure [see Warnings and Precautions (5.1) ] . Infusion-Related Reactions Advise patients about the symptoms of infusion related reactions and to seek immediate medical attention if they develop any of these symptoms [see Warnings and Precautions (5.2) ] . Myelosuppression Advise patients to contact their healthcare provider for a new onset fever or symptoms of infection. Hand-Foot Syndrome Advise patients to notify their healthcare provider if they experience tingling or burning, redness, flaking, bothersome swelling, small blisters, or small sores on the palms of their hands or soles of their feet (symptoms of Hand-Foot Syndrome) [see Warnings and Precautions (5.3) ] . Stomatitis Advise patients to notify their healthcare provider if they develop painful redness, swelling, or sores in the mouth (symptoms of stomatitis). Embryo-Fetal Toxicity Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider with a known or suspected pregnancy [see Warnings and Precautions (5.5) and Use in Specific Populations (8.1) ]. Advise females and males of reproductive potential to use effective contraception during and for 6 months following treatment with DOXIL liposomal infusion [see Use in Specific Populations (8.3) ] . Lactation Advise females not to breastfeed during treatment with DOXIL liposomal infusion [see Use in Specific Populations (8.2) ]. Infertility Advise females and males of reproductive potential that DOXIL liposomal infusion may cause temporary or permanent infertility [see Use in Specific Populations (8.3) ]. Discoloration of Urine and Body Fluids Inform patients that following DOXIL liposomal infusion administration, a reddish-orange color to the urine and other body fluids may be observed. This nontoxic reaction is due to the color of the product and will dissipate as the drug is eliminated from the body."],"spl_unclassified_section":["Manufactured for: Baxter Healthcare Corporation Deerfield, IL 60015 USA Baxter, Doxil, and Stealth are registered trademarks of Baxter International Inc. HA-30-01-919 USA - 749706"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Administer DOXIL liposomal infusion at an initial rate of 1 mg/min to minimize the risk of infusion reactions. If no infusion-related reactions occur, increase rate of infusion to complete administration over 1 hour. Do not administer as bolus injection or undiluted solution ( 2 ). • Ovarian cancer: 50 mg/m 2 intravenously every 4 weeks ( 2.2 ) • AIDS-related Kaposi’s Sarcoma: 20 mg/m 2 intravenously every 3 weeks ( 2.3 ) • Multiple Myeloma: 30 mg/m 2 intravenously on day 4 following bortezomib ( 2.4 ) 2.1 Important Use Information Do not substitute DOXIL liposomal infusion for other doxorubicin hydrochloride products. Do not administer as an undiluted suspension or as an intravenous bolus [see Warnings and Precautions (5.2) ] . 2.2 Ovarian Cancer The recommended dose of DOXIL liposomal infusion is 50 mg/m 2 intravenously over 60 minutes every 28 days until disease progression or unacceptable toxicity. 2.3 AIDS-Related Kaposi’s Sarcoma The recommended dose of DOXIL liposomal infusion is 20 mg/m 2 intravenously over 60 minutes every 21 days until disease progression or unacceptable toxicity. 2.4 Multiple Myeloma The recommended dose of DOXIL liposomal infusion is 30 mg/m 2 intravenously over 60 minutes on day 4 of each 21-day cycle for eight cycles or until disease progression or unacceptable toxicity. Administer DOXIL liposomal infusion after bortezomib on day 4 of each cycle [see Clinical Studies (14.3) ] . 2.5 Dose Modifications for Adverse Reactions Do not increase DOXIL liposomal infusion after a dose reduction for toxicity. Table 1: Recommended Dose Modifications for Hand-Foot Syndrome, Stomatitis, or Hematologic Adverse Reactions Toxicity Dose Adjustment Hand-Foot Syndrome (HFS) Grade 1: Mild erythema, swelling, or desquamation not interfering with daily activities • If no previous Grade 3 or 4 HFS: no dose adjustment. • If previous Grade 3 or 4 HFS: delay dose up to 2 weeks, then decrease dose by 25%. Grade 2: Erythema, desquamation, or swelling interfering with, but not precluding normal physical activities; small blisters or ulcerations less than 2 cm in diameter • Delay dosing up to 2 weeks or until resolved to Grade 0–1. • Discontinue DOXIL liposomal infusion if no resolution after 2 weeks. • If resolved to Grade 0–1 within 2 weeks: • And no previous Grade 3 or 4 HFS: continue treatment at previous dose. • And previous Grade 3 or 4 toxicity: decrease dose by 25%. Grade 3: Blistering, ulceration, or swelling interfering with walking or normal daily activities; cannot wear regular clothing • Delay dosing up to 2 weeks or until resolved to Grade 0–1, then decrease dose by 25%. • Discontinue DOXIL liposomal infusion if no resolution after 2 weeks. Grade 4: Diffuse or local process causing infectious complications, or a bed ridden state or hospitalization • Delay dosing up to 2 weeks or until resolved to Grade 0–1, then decrease dose by 25%. • Discontinue DOXIL liposomal infusion if no resolution after 2 weeks. Stomatitis Grade 1: Painless ulcers, erythema, or mild soreness • If no previous Grade 3 or 4 toxicity: no dose adjustment. • If previous Grade 3 or 4 toxicity: delay up to 2 weeks then decrease dose by 25%. Grade 2: Painful erythema, edema, or ulcers, but can eat • Delay dosing up to 2 weeks or until resolved to Grade 0–1. • Discontinue DOXIL liposomal infusion if there is no resolution after 2 weeks. • If resolved to Grade 0–1 within 2 weeks: • And no previous Grade 3 or 4 stomatitis: resume treatment at previous dose. • And previous Grade 3 or 4 toxicity: decrease dose by 25%. Grade 3: Painful erythema, edema, or ulcers, and cannot eat • Delay dosing up to 2 weeks or until resolved to Grade 0–1. Decrease dose by 25% and return to original dose interval. • If after 2 weeks there is no resolution, discontinue DOXIL liposomal infusion. Grade 4: Requires parenteral or enteral support • Delay dosing up to 2 weeks or until resolved to Grade 0–1. Decrease dose by 25% and return to original dose interval. • If after 2 weeks there is no resolution, discontinue DOXIL liposomal infusion. Neutropenia or Thrombocytopenia Grade 1 No dose reduction Grade 2 Delay until ANC ≥ 1,500 and platelets ≥ 75,000; resume treatment at previous dose Grade 3 Delay until ANC ≥ 1,500 and platelets ≥ 75,000; resume treatment at previous dose Grade 4 Delay until ANC ≥ 1,500 and platelets ≥ 75,000; resume at 25% dose reduction or continue previous dose with prophylactic granulocyte growth factor Table 2: Recommended Dose Modifications of DOXIL Liposomal Infusion for Toxicity When Administered in Combination With Bortezomib Toxicity DOXIL Liposomal Infusion Fever ≥38°C and ANC <1,000/mm 3 • Withhold dose for this cycle if before Day 4; • Decrease dose by 25%, if after Day 4 of previous cycle. On any day of drug administration after Day 1 of each cycle: • Platelet count <25,000/mm 3 • Hemoglobin <8 g/dL • ANC <500/mm 3 • Withhold dose for this cycle if before Day 4; • Decrease dose by 25%, if after Day 4 of previous cycle AND if bortezomib is reduced for hematologic toxicity. Grade 3 or 4 non-hematologic drug related toxicity Do not dose until recovered to Grade <2, then reduce dose by 25%. For neuropathic pain or peripheral neuropathy, no dosage adjustments are required for DOXIL liposomal infusion. Refer to bortezomib manufacturer’s prescribing information. 2.6 Preparation and Administration Preparation Dilute DOXIL liposomal infusion doses up to 90 mg in 250 mL of 5% Dextrose Injection, USP prior to administration. Dilute doses exceeding 90 mg in 500 mL of 5% Dextrose Injection, USP prior to administration. Refrigerate diluted DOXIL liposomal infusion at 2°C to 8°C (36°F to 46°F) and administer within 24 hours. Administration Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if a precipitate or foreign matter is present. Do not use with in-line filters. Administer the first dose of DOXIL liposomal infusion at an initial rate of 1 mg/min. If no infusion-related adverse reactions are observed, increase the infusion rate to complete the administration of the drug over one hour [see Warnings and Precautions (5.2) ]. Do not rapidly flush the infusion line. Do not mix DOXIL liposomal infusion with other drugs. Management of Suspected Extravasation Discontinue DOXIL liposomal infusion for burning or stinging sensation or other evidence indicating perivenous infiltration or extravasation. Manage confirmed or suspected extravasation as follows: • Do not remove the needle until attempts are made to aspirate extravasated fluid • Do not flush the line • Avoid applying pressure to the site • Apply ice to the site intermittently for 15 minute 4 times a day for 3 days • If the extravasation is in an extremity, elevate the extremity 2.7 Procedure for Proper Handling and Disposal DOXIL liposomal infusion is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 If DOXIL liposomal infusion comes into contact with skin or mucosa, immediately wash thoroughly with soap and water."],"spl_product_data_elements":["DOXIL doxorubicin hydrochloride doxorubicin hydrochloride doxorubicin SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE hydrogenated soybean lecithin cholesterol ammonium sulfate histidine hydrochloric acid sodium hydroxide sucrose DOXIL doxorubicin hydrochloride doxorubicin hydrochloride doxorubicin SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE hydrogenated soybean lecithin cholesterol ammonium sulfate histidine hydrochloric acid sodium hydroxide sucrose"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS DOXIL (doxorubicin hydrochloride liposome injection): 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) translucent, red liposomal dispersion in single dose vials. Doxorubicin hydrochloride liposomal injection: 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) in single dose vials ( 3 )"],"clinical_pharmacology_table":["
Table 8: Pharmacokinetic Parameters of Total Doxorubicin from DOXIL Liposomal Infusion in Patients With AIDS-Related Kaposi’s Sarcoma
Dose
Parameter (units)10 mg/m220 mg/m2
N=23 Mean ± Standard Error
Peak Plasma Concentration (µg/mL)4.12 ± 0.2158.34 ± 0.49
Plasma Clearance (L/h/m2)0.056 ± 0.010.041 ± 0.004
Steady State Volume of Distribution (L/m2)2.83 ± 0.1452.72 ± 0.120
AUC (µg/mL∙h)277 ± 32.9590 ± 58.7
First Phase (λ1) Half-Life (h)4.7 ± 1.15.2 ± 1.4
Second Phase (λ1) Half-Life (h)52.3 ± 5.655.0 ± 4.8
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS • Lactation: Discontinue breastfeeding ( 8.2 ). 8.1 Pregnancy Risk Summary Based on findings in animals and its mechanism of action, DOXIL liposomal infusion can cause fetal harm when administered to a pregnant woman; avoid the use of DOXIL liposomal infusion during the 1 st trimester. In animal reproduction studies, DOXIL liposomal infusion was embryotoxic in rats and abortifacient in rabbits following intravenous administration during organogenesis at doses approximately 0.12 times the recommended clinical dose (see Data ) . Available human data do not establish the presence or absence of major birth defects and miscarriage related to the use of doxorubicin hydrochloride during the 2 nd and 3 rd trimesters. Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the background risk in the U.S. general population of major birth defects is 2–4% and of miscarriage is 15–20% of clinically recognized pregnancies. Data Animal Data DOXIL liposomal infusion was embryotoxic at doses of 1 mg/kg/day in rats and was embryotoxic and abortifacient at 0.5 mg/kg/day in rabbits (both doses are about 0.12 times the recommended dose of 50 mg/m 2 human dose on a mg/m 2 basis). Embryotoxicity was characterized by increased embryo-fetal deaths and reduced live litter sizes. 8.2 Lactation Risk Summary It is not known whether DOXIL liposomal infusion is present in human milk. Because many drugs, including anthracyclines, are excreted in human milk and because of the potential for serious adverse reactions in breastfed infants from DOXIL liposomal infusion, discontinue breastfeeding during treatment with DOXIL liposomal infusion. 8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiating DOXIL liposomal infusion. Contraception Females DOXIL liposomal infusion can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] . Advise females of reproductive potential to use effective contraception during and for 6 months after treatment with DOXIL liposomal infusion. Males DOXIL liposomal infusion may damage spermatozoa and testicular tissue, resulting in possible genetic fetal abnormalities. Males with female sexual partners of reproductive potential should use effective contraception during and for 6 months after treatment with DOXIL liposomal infusion [see Non-clinical Toxicology (13.1) ]. Infertility Females In females of reproductive potential, DOXIL liposomal infusion may cause infertility and result in amenorrhea. Premature menopause can occur with doxorubicin hydrochloride. Recovery of menses and ovulation is related to age at treatment . Males DOXIL liposomal infusion may result in oligospermia, azoospermia, and permanent loss of fertility. Sperm counts have been reported to return to normal levels in some men. This may occur several years after the end of therapy [see Non-clinical Toxicology (13.1) ] . 8.4 Pediatric Use The safety and effectiveness of DOXIL liposomal infusion in pediatric patients have not been established. 8.5 Geriatric Use Clinical studies of DOXIL liposomal infusion conducted in patients with either epithelial ovarian cancer (Trial 4) or with AIDS-related Kaposi’s sarcoma (Trial 5) did not contain sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger subjects. In Trial 6, of 318 patients treated with DOXIL liposomal infusion in combination with bortezomib for multiple myeloma, 37% were 65 years of age or older and 8% were 75 years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients. 8.6 Hepatic Impairment The pharmacokinetics of DOXIL liposomal infusion has not been adequately evaluated in patients with hepatic impairment. Doxorubicin is eliminated in large part by the liver. Reduce DOXIL liposomal infusion for serum bilirubin of 1.2 mg/dL or higher."],"dosage_and_administration_table":["If no previous Grade 3 or 4 HFS: no dose adjustment.If previous Grade 3 or 4 HFS: delay dose up to 2 weeks, then decrease dose by 25%.Delay dosing up to 2 weeks or until resolved to Grade 0–1.Discontinue DOXIL liposomal infusion if no resolution after 2 weeks.If resolved to Grade 0–1 within 2 weeks: And no previous Grade 3 or 4 HFS: continue treatment at previous dose.And previous Grade 3 or 4 toxicity: decrease dose by 25%.Delay dosing up to 2 weeks or until resolved to Grade 0–1, then decrease dose by 25%.Discontinue DOXIL liposomal infusion if no resolution after 2 weeks.Delay dosing up to 2 weeks or until resolved to Grade 0–1, then decrease dose by 25%.Discontinue DOXIL liposomal infusion if no resolution after 2 weeks.If no previous Grade 3 or 4 toxicity: no dose adjustment.If previous Grade 3 or 4 toxicity: delay up to 2 weeks then decrease dose by 25%.Delay dosing up to 2 weeks or until resolved to Grade 0–1.Discontinue DOXIL liposomal infusion if there is no resolution after 2 weeks.If resolved to Grade 0–1 within 2 weeks: And no previous Grade 3 or 4 stomatitis: resume treatment at previous dose.And previous Grade 3 or 4 toxicity: decrease dose by 25%.Delay dosing up to 2 weeks or until resolved to Grade 0–1. Decrease dose by 25% and return to original dose interval.If after 2 weeks there is no resolution, discontinue DOXIL liposomal infusion.Delay dosing up to 2 weeks or until resolved to Grade 0–1. Decrease dose by 25% and return to original dose interval.If after 2 weeks there is no resolution, discontinue DOXIL liposomal infusion.
Table 1: Recommended Dose Modifications for Hand-Foot Syndrome, Stomatitis, or Hematologic Adverse Reactions
ToxicityDose Adjustment
Hand-Foot Syndrome (HFS)
Grade 1: Mild erythema, swelling, or desquamation not interfering with daily activities
••
Grade 2: Erythema, desquamation, or swelling interfering with, but not precluding normal physical activities; small blisters or ulcerations less than 2 cm in diameter
•••••
Grade 3: Blistering, ulceration, or swelling interfering with walking or normal daily activities; cannot wear regular clothing
••
Grade 4: Diffuse or local process causing infectious complications, or a bed ridden state or hospitalization
••
Stomatitis
Grade 1: Painless ulcers, erythema, or mild soreness
••
Grade 2: Painful erythema, edema, or ulcers, but can eat
•••••
Grade 3: Painful erythema, edema, or ulcers, and cannot eat
••
Grade 4: Requires parenteral or enteral support
••
Neutropenia or Thrombocytopenia
Grade 1No dose reduction
Grade 2Delay until ANC ≥ 1,500 and platelets ≥ 75,000; resume treatment at previous dose
Grade 3Delay until ANC ≥ 1,500 and platelets ≥ 75,000; resume treatment at previous dose
Grade 4Delay until ANC ≥ 1,500 and platelets ≥ 75,000; resume at 25% dose reduction or continue previous dose with prophylactic granulocyte growth factor
","Withhold dose for this cycle if before Day 4;Decrease dose by 25%, if after Day 4 of previous cycle.Platelet count <25,000/mm3Hemoglobin <8 g/dLANC <500/mm3Withhold dose for this cycle if before Day 4;Decrease dose by 25%, if after Day 4 of previous cycle AND if bortezomib is reduced for hematologic toxicity.
Table 2: Recommended Dose Modifications of DOXIL Liposomal Infusion for Toxicity When Administered in Combination With Bortezomib
ToxicityDOXIL Liposomal Infusion
Fever ≥38°C and ANC <1,000/mm3
••
On any day of drug administration after Day 1 of each cycle:
•••
••
Grade 3 or 4 non-hematologic drug related toxicityDo not dose until recovered to Grade <2, then reduce dose by 25%.
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 20 mg Vial Carton NDC 0338-0063-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) 20 mg in 10 mL (2 mg/mL) Single-Dose Vial. Discard unused portion. LIPOSOMAL FORMULATION - DO NOT SUBSTITUTE FOR DOXORUBICIN Hydrochloride FOR INTRAVENOUS INFUSION ONLY Rx only Cytotoxic HA-65-01-805 Refrigerate, 2°-8°C (36°-46°F). Do Not Freeze. See package insert for dosage information. Baxter Healthcare Corporation Deerfield, IL 60015 Baxter, Doxil, and Stealth are registered trademarks of Baxter International Inc., or its subsidiaries. Bar Code 0100303380063017 Bar Code 696988 LOT EXP Carton Label US 749703 882 Barcode NDC 0338-0063-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) 20 mg in 10 mL (2 mg/mL) Single-Dose Vial. Discard unused portion. LIPOSOMAL FORMULATION - DO NOT SUBSTITUTE FOR DOXORUBICIN Hydrochloride FOR INTRAVENOUS INFUSION ONLY AFTER DILUTION. Refrigerate, 2°-8°C (36°-46°F). Do Not Freeze. Cytotoxic Rx only Baxter Logo NDC 0338-0063-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) Use 5% Dextrose Injection, USP when diluting DOXIL. Bar Code 3 03380 06301 7 Note: Liposomal formulation. Recommended Dosage: see prescribing information. NDC 0338-0063-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) NDC 0338-0063-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) LIPOSOMAL FORMULATION - DO NOT SUBSTITUTE FOR DOXORUBICIN Hydrochloride Manufactured for: Baxter Healthcare Corporation Deerfield, IL 60015 Product of Italy Baxter, Doxil, and Stealth are registered trademarks of Baxter International Inc., or its subsidiaries. GTIN 00303380063017 2D Bar Code S/N EXP LOT NDC 0338-0063-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) Each mL contains doxorubicin Hydrochloride, 2 mg. STEALTH liposome carriers are composed of cholesterol, 3.19 mg; fully hydrogenated soy phosphatidylcholine (HSPC), 9.58 mg; and N-(carbonyl- methoxypolyethylene glycol 2000)-1,2-distearoyl-sn- glycerol-3-phosphoethanolamine sodium salt (MPEG-DSPE), 3.19 mg. Each mL also contains ammonium sulfate, approximately 0.6 mg; histidine, 1.55 mg; hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (6.0 to 7.0) and sucrose, 94 mg. HA-80-02-881 NDC 0338-0063-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) 20 mg in 10 mL (2 mg/mL) Single-Dose Vial. Discard unused portion. LIPOSOMAL FORMULATION - DO NOT SUBSTITUTE FOR DOXORUBICIN Hydrochloride FOR INTRAVENOUS INFUSION ONLY Refrigerate, 2°-8°C (36°-46°F). Do Not Freeze. Cytotoxic Rx only Baxter Logo NDC 0338-0063-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) N 3 Bar Code 0338-0063-01 7 Note: Liposomal formulation. See package insert for dosage information. USA 6943440 882 Bar Code NDC 0338-0063-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) LIPOSOMAL FORMULATION - DO NOT SUBSTITUTE FOR DOXORUBICIN Hydrochloride Manufactured for: Baxter Healthcare Corporation Deerfield, IL 60015 Product Taiwan Baxter, Doxil, and Stealth are registered trademarks of Baxter International Inc., or its subsidiaries. NDC 0338-0063-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) GTIN 00303380063017 Bar Code S/N EXP LOT NDC 0338-0063-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) Each mL contains doxorubicin Hydrochloride, 2 mg. STEALTH liposome carriers are composed of cholesterol, 3.19 mg; fully hydrogenated soy phosphatidylcholine (HSPC), 9.58 mg; and N-(carbonyl- methoxypolyethylene glycol 2000)-1,2-distearoyl-sn- glycerol-3-phosphoethanolamine sodium salt (MPEG-DSPE), 3.19 mg. Each mL also contains ammonium sulfate, approximately 0.6 mg; histidine; hydrochloric acid and/or sodium hydroxide; and sucrose. HA-80-02-880 NDC 0338-0067-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) 50 mg in 25 mL (2 mg/mL) Single-Dose Vial. Discard unused portion. LIPOSOMAL FORMULATION - DO NOT SUBSTITUTE FOR DOXORUBICIN Hydrochloride FOR INTRAVENOUS INFUSION ONLY Rx only Cytotoxic HA-65-01-806 Refrigerate, 2°-8°C (36°-46°F). Do Not Freeze. See package insert for dosage information. Baxter Healthcare Corporation Deerfield, IL 60015 Baxter, Doxil, and Stealth are registered trademarks of Baxter International Inc., or its subsidiaries. Bar Code 0100303380067015 Bar Code 696987 LOT EXP Carton Label US 749704 882 Barcode NDC 0338-0067-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) 50 mg in 25 mL (2 mg/mL) Single-Dose Vial. Discard unused portion. LIPOSOMAL FORMULATION - DO NOT SUBSTITUTE FOR DOXORUBICIN Hydrochloride FOR INTRAVENOUS INFUSION ONLY AFTER DILUTION. Refrigerate, 2°-8°C (36°-46°F). Do Not Freeze. Cytotoxic Rx only Baxter Logo NDC 0338-0067-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) Use 5% Dextrose Injection, USP when diluting DOXIL. Bar Code 3 03380 06701 5 Note: Liposomal formulation. Recommended Dosage: see prescribing information. NDC 0338-0067-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) NDC 0338-0067-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) LIPOSOMAL FORMULATION - DO NOT SUBSTITUTE FOR DOXORUBICIN Hydrochloride Manufactured for: Baxter Healthcare Corporation Deerfield, IL 60015 Product of Italy Baxter, Doxil, and Stealth are registered trademarks of Baxter International Inc., or its subsidiaries. GTIN 00303380067015 2D Bar Code S/N EXP LOT NDC 0338-0067-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) Each mL contains doxorubicin Hydrochloride, 2 mg. STEALTH liposome carriers are composed of cholesterol, 3.19 mg; fully hydrogenated soy phosphatidylcholine (HSPC), 9.58 mg; and N-(carbonyl- methoxypolyethylene glycol 2000)-1,2-distearoyl-sn- glycerol-3-phosphoethanolamine sodium salt (MPEG-DSPE), 3.19 mg. Each mL also contains ammonium sulfate, approximately 0.6 mg; histidine, 1.55 mg; hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (6.0 to 7.0) and sucrose, 94 mg. HA-80-02-883 NDC 0338-0067-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) 50 mg in 25 mL (2 mg/mL) Single-Dose Vial. Discard unused portion. LIPOSOMAL FORMULATION - DO NOT SUBSTITUTE FOR DOXORUBICIN Hydrochloride FOR INTRAVENOUS INFUSION ONLY Refrigerate, 2°-8°C (36°-46°F). Do Not Freeze. Cytotoxic Rx only Baxter Logo NDC 0338-0067-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) N 3 Bar Code 0338-0067-01 5 Note: Liposomal formulation. See package insert for dosage information. USA 693385 882 Bar Code NDC 0338-0067-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) LIPOSOMAL FORMULATION - DO NOT SUBSTITUTE FOR DOXORUBICIN Hydrochloride Manufactured for: Baxter Healthcare Corporation Deerfield, IL 60015 Product of Taiwan Baxter, Doxil, and Stealth are registered trademarks of Baxter International Inc., or its subsidiaries. NDC 0338-0067-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) GTIN 00303380067015 Bar Code S/N EXP LOT NDC 0338-0067-01 DOXIL (DOXOrubicin Hydrochloride liposome injection) Each mL contains doxorubicin Hydrochloride, 2 mg. STEALTH liposome carriers are composed of cholesterol, 3.19 mg; fully hydrogenated soy phosphatidylcholine (HSPC), 9.58 mg; and N-(carbonyl- methoxypolyethylene glycol 2000)-1,2-distearoyl-sn- glycerol-3-phosphoethanolamine sodium salt (MPEG-DSPE), 3.19 mg. Each mL also contains ammonium sulfate, approximately 0.6 mg; histidine; hydrochloric acid and/or sodium hydroxide; and sucrose. HA-80-02-882 Representative 20 mg Container Label Representative Carton Label 0338-0063-01 Italy 1 of 2 Representative Carton Label 0338-0063-01 Italy 2 of 2 Representative Carton label 20 mg Taiwan Representative Container Label 50 mg Representative Carton Label 0338-0067-01 Italy 1 of 2 Representative Carton Label 0338-0067-01 Italy 2 of 2 Representative Carton Label 50 mg Taiwan"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility Mutagenicity or carcinogenicity studies have not been conducted with DOXIL liposomal infusion, however doxorubicin was shown to be mutagenic in the in vitro Ames assay, and clastogenic in multiple in vitro assays (CHO cell, V79 hamster cell, human lymphoblast, and SCE assays) and the in vivo mouse micronucleus assay. The possible adverse effects on fertility in animals have not been adequately evaluated. DOXIL liposomal infusion resulted in mild to moderate ovarian and testicular atrophy in mice after administration of a single dose of 36 mg/kg (about 2 times the 50 mg/m 2 human dose on a mg/m 2 basis). Decreased testicular weights and hypospermia were observed in rats after repeat doses ≥ 0.25 mg/kg/day (about 0.03 times the 50 mg/m 2 human dose on a mg/m 2 basis), and diffuse degeneration of the seminiferous tubules and a marked decrease in spermatogenesis were observed in dogs after repeat doses of 1 mg/kg/day (about 0.4 times the 50 mg/m 2 human dose on a mg/m 2 basis)."]},"tags":[],"safety":{"boxedWarnings":["WARNING: CARDIOMYOPATHY and INFUSION-RELATED REACTIONS • DOXIL liposomal infusion can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 mg/m 2 to 550 mg/m 2 . Assess left ventricular cardiac function prior to initiation of DOXIL liposomal infusion and during and after treatment [see Warnings and Precautions (5.1) ] . • Serious, life-threatening, and fatal infusion-related reactions can occur with DOXIL liposomal infusion Acute infusion-related reactions occurred in 11% of patients with solid tumors. Withhold DOXIL liposomal infusion for infusion-related reactions and resume at a reduced rate. Discontinue DOXIL liposomal infusion for serious or life-threatening infusion-related reactions [see Warnings and Precautions (5.2) ] . WARNING: CARDIOMYOPATHY and INFUSION- RELATED REACTIONS See full prescribing information for complete boxed warning. • DOXIL liposomal infusion can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 mg/m 2 to 550 mg/m 2 . Assess left ventricular cardiac function prior to initiation of DOXIL liposomal infusion, during treatment, and after treatment ( 5.1 ). • Serious, life-threatening, and fatal infusion‑related reactions can occur. Acute infusion-related reactions occurred in 11% of patients with solid tumors. Withhold DOXIL liposomal infusion for infusion-related reactions and resume at a reduced rate. Discontinue DOXIL liposomal infusion for serious or life-threatening infusion-related reactions ( 5.2 )."],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Neutropenia 500 – <1000/mm 3","drugRate":"8%","_validated":true,"placeboRate":"14%"},{"effect":"Neutropenia <500/mm 3","drugRate":"4.2%","_validated":true,"placeboRate":"62%"},{"effect":"Anemia 6.5 – <8 g/dL","drugRate":"5%","_validated":true,"placeboRate":"25%"},{"effect":"Anemia < 6.5 g/dL","drugRate":"0.4%","_validated":true,"placeboRate":"4.3%"},{"effect":"Thrombocytopenia 10,000 – <50,000/mm 3","drugRate":"1.3%","_validated":true,"placeboRate":"17%"},{"effect":"Thrombocytopenia <10,000/mm 3","drugRate":"0.0%","_validated":true,"placeboRate":"17%"},{"effect":"Asthenia","drugRate":"40%","_validated":true,"placeboRate":"52%"},{"effect":"Fever","drugRate":"21%","_validated":true,"placeboRate":"31%"},{"effect":"Mucous Membrane Disorder","drugRate":"14%","_validated":true,"placeboRate":"3.4%"},{"effect":"Back Pain","drugRate":"12%","_validated":true,"placeboRate":"10%"},{"effect":"Infection","drugRate":"12%","_validated":true,"placeboRate":"6%"},{"effect":"Headache","drugRate":"11%","_validated":true,"placeboRate":"15%"},{"effect":"Nausea","drugRate":"46%","_validated":true,"placeboRate":"63%"},{"effect":"Stomatitis","drugRate":"41%","_validated":true,"placeboRate":"15%"},{"effect":"Vomiting","drugRate":"33%","_validated":true,"placeboRate":"44%"},{"effect":"Diarrhea","drugRate":"21%","_validated":true,"placeboRate":"35%"},{"effect":"Anorexia","drugRate":"20%","_validated":true,"placeboRate":"22%"},{"effect":"Dyspepsia","drugRate":"12%","_validated":true,"placeboRate":"14%"},{"effect":"Pharyngitis","drugRate":"16%","_validated":true,"placeboRate":"18%"},{"effect":"Dyspnea","drugRate":"15%","_validated":true,"placeboRate":"23%"},{"effect":"Cough increased","drugRate":"10%","_validated":true,"placeboRate":"12%"},{"effect":"Hand-foot syndrome","drugRate":"51%","_validated":true,"placeboRate":"0.9%"},{"effect":"Rash","drugRate":"29%","_validated":true,"placeboRate":"12%"},{"effect":"Alopecia","drugRate":"19%","_validated":true,"placeboRate":"52%"}],"contraindications":["DOXIL liposomal infusion is contraindicated in patients with a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride.","Hypersensitivity reactions to doxorubicin hydrochloride or the components of DOXIL liposomal infusion."],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=doxil","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:42:53.661827+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Doxil","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:43:01.537603+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:43:00.214413+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=doxil","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:43:00.960482+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:51.432259+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: CARDIOMYOPATHY and INFUSION-RELATED REACTIONS • DOXIL liposomal infusion can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 mg/m 2 to 550 mg/m 2 . Assess left ventricular cardiac function prior to initiation of DOXIL liposomal infusion and during and after treatment [see Warnings and Precautions (5.1) ] . • Serious, life-threatening, and fatal infusion-related reactions can occu","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:51.432320+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action The active ingredient of DOXIL liposomal infusion is doxorubicin hydrochloride. The mechanism of action of doxorubicin hydrochloride is thought to be related to its ability to bind DNA and inhibit nucleic acid synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and induction of mutagenesis and chromosomal aberrations.","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:43:16.923088+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL53463/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:43:01.436234+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling. • Cardiomyopathy [see Warnings and Precautions (5.1) ] • Infusion-Related Reactions [see Warnings and Precautions (5.2) ] • Hand-Foot Syndrome [see Warnings and Precautions (5.3) ] • Secondary Oral Neoplasms [see Warnings and Precautions (5.4) ] Most common adverse reactions (>20%) are asthenia, fatigue, fever, anorexia, nausea, vomiting, stomatitis, diarrhea, constipation, hand-fo","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:44:04.736644+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:44:09.481519+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA050718","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:51.432333+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"917eddf9-1d3f-4abe-8c81-d33b066e5bae","title":"DOXIL (DOXORUBICIN HYDROCHLORIDE) INJECTION, SUSPENSION, LIPOSOMAL [BAXTER HEALTHCARE CORPORATION]"},"ecosystem":[],"mechanism":{"target":"DNA","explanation":"Doxorubicin works by penetrating cells quickly and binding to DNA near the nucleus. This binding disrupts the synthesis of nucleic acids, halts cell division, and causes genetic mutations and chromosomal abnormalities.","oneSentence":"Doxorubicin binds DNA, inhibits nucleic acid synthesis, and induces mutagenesis and chromosomal aberrations.","technicalDetail":"Cell structure studies have demonstrated rapid cell penetration and perinuclear chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and induction of mutagenesis and chromosomal aberrations."},"_scrapedAt":"2026-03-27T23:28:26.629Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Doxorubicin","title":"Doxorubicin","extract":"Doxorubicin, sold under the brand name Adriamycin among others, is a chemotherapy medication used to treat cancer. This includes breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. It is often used together with other chemotherapy agents. Doxorubicin is given by injection into a vein."},"references":[],"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-19T23:44:11.366758+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT02306161","phase":"PHASE3","title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":"Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow","enrollment":312},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT02839707","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":444},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT05691478","phase":"PHASE2, PHASE3","title":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-03","conditions":"High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1122},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":"Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer","enrollment":60},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":"Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma","enrollment":600},{"nctId":"NCT07494565","phase":"PHASE2","title":"Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-05","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive","enrollment":60},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT06422806","phase":"PHASE3","title":"Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-11","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","enrollment":365},{"nctId":"NCT05711615","phase":"PHASE1","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-06","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma","enrollment":30},{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT00066443","phase":"PHASE1, PHASE2","title":"Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":93},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":"Breast Neoplasms","enrollment":1200},{"nctId":"NCT02180867","phase":"PHASE2, PHASE3","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-07-11","conditions":"Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma","enrollment":140},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT00740805","phase":"PHASE1","title":"Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-18","conditions":"Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Solid Neoplasm","enrollment":81},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":349},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT06058377","phase":"PHASE3","title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-27","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma","enrollment":3680},{"nctId":"NCT05210374","phase":"PHASE1","title":"Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2023-03-09","conditions":"Relapsed Sarcomas","enrollment":24},{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":"Breast Neoplasms","enrollment":1000},{"nctId":"NCT04092270","phase":"PHASE1","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-07","conditions":"Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":54},{"nctId":"NCT07496229","phase":"PHASE1, PHASE2","title":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","status":"NOT_YET_RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2026-03","conditions":"T-cell Lymphomas","enrollment":165},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT03937830","phase":"PHASE2","title":"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-10","conditions":"Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma","enrollment":27},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT04008797","phase":"PHASE1, PHASE2","title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2019-07-11","conditions":"Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular","enrollment":301},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT04677816","phase":"PHASE2","title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-22","conditions":"Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer","enrollment":50},{"nctId":"NCT04799275","phase":"PHASE2, PHASE3","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":"Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":422},{"nctId":"NCT07214779","phase":"PHASE3","title":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-12-09","conditions":"Ovarian Cancer","enrollment":466},{"nctId":"NCT07215585","phase":"PHASE3","title":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-11","conditions":"Large B-cell Lymphoma","enrollment":420},{"nctId":"NCT07486310","phase":"PHASE2","title":"Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-01","conditions":"Advanced Gastric Cancer","enrollment":30},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT05748834","phase":"PHASE2","title":"Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-07-24","conditions":"Breast Cancer","enrollment":36},{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT06563245","phase":"PHASE2, PHASE3","title":"Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2024-09-25","conditions":"Classical Hodgkin Lymphoma, Child, Adolescent","enrollment":96},{"nctId":"NCT04881838","phase":"PHASE3","title":"CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2021-03-01","conditions":"Pediatric Anaplastic Large Cell Lymphoma","enrollment":172},{"nctId":"NCT05610735","phase":"PHASE1, PHASE2","title":"Combination Therapy for Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Sham Sunder Kakar","startDate":"2024-09-25","conditions":"Recurrent Ovarian Cancer","enrollment":72},{"nctId":"NCT07286266","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-24","conditions":"Ovarian Neoplasms","enrollment":450},{"nctId":"NCT03517449","phase":"PHASE3","title":"Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2018-06-11","conditions":"Endometrial Neoplasms","enrollment":827},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT03793361","phase":"PHASE2","title":"Phase II Study of Regorafenib as Maintenance Therapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2019-05-15","conditions":"Metastatic Soft Tissue Sarcoma","enrollment":127},{"nctId":"NCT06549595","phase":"PHASE3","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-07","conditions":"Untreated Follicular Lymphoma","enrollment":1018},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":""},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT06047080","phase":"PHASE3","title":"An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-18","conditions":"Large B-Cell Lymphoma","enrollment":1130},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT04031677","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2021-01-20","conditions":"Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma","enrollment":250},{"nctId":"NCT07477457","phase":"PHASE2","title":"A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-11","conditions":"Osteosarcoma, Metastasis","enrollment":45},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":"Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma","enrollment":38},{"nctId":"NCT00379340","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-04-30","conditions":"Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor","enrollment":395},{"nctId":"NCT06072781","phase":"PHASE3","title":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Verastem, Inc.","startDate":"2024-03-18","conditions":"Low Grade Serous Ovarian Cancer","enrollment":270},{"nctId":"NCT00006721","phase":"PHASE3","title":"S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-03","conditions":"Lymphoma","enrollment":571},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT04001829","phase":"PHASE2","title":"Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-08-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":249},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT02203526","phase":"PHASE1","title":"Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-08-14","conditions":"Primary Central Nervous System Lymphoma","enrollment":93},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT05453500","phase":"PHASE2","title":"Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-03-27","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":30},{"nctId":"NCT04729387","phase":"PHASE3","title":"Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-22","conditions":"Ovarian Cancer","enrollment":358},{"nctId":"NCT04293393","phase":"PHASE2","title":"Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2020-10-02","conditions":"Early Breast Cancer","enrollment":200},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT06088290","phase":"PHASE3","title":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)","status":"RECRUITING","sponsor":"PharmaMar","startDate":"2023-09-21","conditions":"Leiomyosarcoma","enrollment":450},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":"Leukemia","enrollment":171},{"nctId":"NCT07463313","phase":"PHASE2, PHASE3","title":"6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03","conditions":"Thymoma and Thymic Carcinoma","enrollment":116},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT07286331","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-09","conditions":"Neoplasms, Endometrial","enrollment":600},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT01419561","phase":"PHASE2","title":"Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-08","conditions":"KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8","enrollment":140},{"nctId":"NCT07076186","phase":"PHASE2","title":"Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-02","conditions":"Uterine Leiomyosarcoma","enrollment":48},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT07460986","phase":"PHASE1, PHASE2","title":"A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07","conditions":"Sarcoma of Soft Tissue","enrollment":278},{"nctId":"NCT05959889","phase":"NA","title":"Effect of Montelukast on Doxorubicin Induced Cardiotoxicity in Breast Cancer","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2023-03-01","conditions":"Breast Cancer, Doxorubicin Induced Cardiotoxicity","enrollment":50},{"nctId":"NCT05661201","phase":"PHASE1","title":"NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2023-04-12","conditions":"Solid Tumor, KRAS Mutation-Related Tumors","enrollment":24},{"nctId":"NCT05581030","phase":"PHASE1","title":"CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-05-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":7},{"nctId":"NCT01928589","phase":"NA","title":"Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Richard Zellars","startDate":"2014-01-16","conditions":"Breast Cancer, Adenocarcinoma of the Breast","enrollment":81},{"nctId":"NCT07254091","phase":"EARLY_PHASE1","title":"Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2026-01-30","conditions":"Pancreatic Cancer","enrollment":10},{"nctId":"NCT02446600","phase":"PHASE3","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-28","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma","enrollment":579},{"nctId":"NCT06745076","phase":"PHASE2","title":"Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-03-06","conditions":"Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8","enrollment":125},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT07044336","phase":"PHASE3","title":"Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-01","conditions":"Endometrial Cancer, Malignant Solid Tumour","enrollment":700}],"_emaApprovals":[],"_faersSignals":[{"count":1430,"reaction":"ALOPECIA"},{"count":1121,"reaction":"HAIR TEXTURE ABNORMAL"},{"count":1119,"reaction":"HAIR COLOUR CHANGES"},{"count":1115,"reaction":"HAIR DISORDER"},{"count":963,"reaction":"MADAROSIS"},{"count":427,"reaction":"NAUSEA"},{"count":407,"reaction":"FEBRILE NEUTROPENIA"},{"count":387,"reaction":"OFF LABEL USE"},{"count":358,"reaction":"FATIGUE"},{"count":320,"reaction":"VOMITING"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous"},"crossReferences":{"rxcui":"80773","chemblId":"CHEMBL53463","pubchemSID":"49846798"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":719,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Doxil","genericName":"doxil","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":7,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":2},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-19T23:44:11.366758+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}